About Afimmune

Afimmune, headquartered in Dublin, Ireland, is a drug discovery and development company working on new medicines to improve the quality of life for people with diseases for which existing therapies are ineffective or unsafe. Afimmune has assets in various stages of clinical and pre-clinical development. Afimmune pipeline

Latest News

November 14, 2019
Published by Adelle McGourty at November 14, 2019
Categories

Clinical Data Showing The Potential Of Epeleuton As A Treatment For Hypertriglyceridemia And Diabetes As Well As Cardiovascular Disease Prevention Will Be Presented At The American Heart Association’s 2019 Scientific Sessions, November 16-18

Dublin, Ireland, 14th November 2019 – Afimmune, a privately held, clinical stage biopharmaceutical company, today announced that results of its investigational drug Epeleuton will be presented at […]
Do you like it?0
Read more
December 18, 2018
Published by Adelle McGourty at December 18, 2018
Categories

Afimmune receives method of use patent allowance for Oral AF102 in the US

Dublin, Ireland, 18th December 2018 – Afimmune, a privately held clinical stage drug discovery and development company, today announced receipt of allowance for a patent application in […]
Do you like it?0
Read more

More Press Releases

Join our mailing list

Contact us

t: +353 1 2946380 e: [email protected]

Latest Publications

August 11, 2020
Published by micadmin at August 11, 2020
Categories

Effects of Epeleuton, a Novel Synthetic Second‐Generation n‐3 Fatty Acid, on Non‐Alcoholic Fatty Liver Disease, Triglycerides, Glycemic Control, and Cardiometabolic and Inflammatory Markers

The Epeleuton Phase 2a data was accepted for publication in the peer reviewed Journal of the American Heart Association. The paper can be found here. In […]
Do you like it?0
Read more